➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Dow
Johnson and Johnson
McKesson
Boehringer Ingelheim

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Claims for Patent: 5,721,139

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,721,139
Title: Isolating and culturing schwann cells
Abstract:A method for enhancing the survival and/or proliferation of Schwann cells (especially human Schwann cells) in cell culture is disclosed which involves culturing the cells in serum free culture medium comprising gas6 and other mitogenic agents, such as heregulin and forskolin. The culturing step is generally preceded by a pre-incubation period wherein nerve tissue comprising the Schwann cells is cultured under appropriate conditions and for a period of time such that demyelination occurs. The isolated Schwann cells can be used as cellular prostheses to treat patients with nervous system injuries. The invention also provides a cell culture medium for culturing Schwann cells.
Inventor(s): Mather; Jennie P. (Millbrae, CA), Li; Ronghao (Millbrae, CA), Chen; Jian (Burlingame, CA)
Assignee: Genentech, Inc. (South San Francisco, CA)
Application Number:08/435,436
Patent Claims:1. A method for enhancing the survival or proliferation of Schwann cells in cell culture without supporting the growth of fibroblasts, said method comprising culturing the Schwann cells in serum free culture medium, wherein the culture medium comprises a nutrient solution for growing mammalian cells supplemented with a first mitogenic agent which is a Rse/Axl receptor activator and a second mitogenic agent, wherein the first and second mitogenic agents are each present in the culture medium in an amount effective to enhance survival or proliferation of the Schwann cells.

2. The method of claim 1 wherein the Schwann cells are human Schwann cells.

3. The method of claim 1 wherein the Rse/Axl receptor activator is gas6.

4. The method of claim 1 wherein the culturing is performed in the presence of laminin.

5. The method of claim 4 comprising culturing the Schwann cells in a laminin-coated culture plate.

6. The method of claim 1 wherein the second mitogenic agent is an erbB receptor activator.

7. The method of claim 1 wherein the second mitogenic agent is an agent which elevates cAMP levels.

8. The method of claim 7 wherein the agent which elevates cAMP levels is forskolin.

9. The method of claim 1 wherein said culture medium additionally comprises a molecule or composition which provides Fe ions to the Schwann cells, wherein the molecule or composition is present in the culture medium in an amount effective to enhance survival or proliferation of the Schwann cells cultured therein.

10. The method of claim 9 wherein said molecule or composition which provides Fe ions to the Schwann cells is transferrin.

11. The method of claim 1 wherein the second mitogenic agent is insulin or an insulin like growth factor, and the insulin or insulin like growth factor is present in the culture medium in an amount effective to enhance survival or proliferation of Schwann cells cultured therein.

12. The method of claim 1 wherein said culture medium additionally comprises Vitamin E, wherein the concentration of Vitamin E in the culture medium is in the range form 0.1 .mu.g/ml to 100 .mu.g/ml.

13. The method of claim 1 wherein said culture medium additionally comprises a protease inhibitor, wherein the concentration of protease inhibitor in the culture medium is in the range from 1 .mu.g/ml to 500 .mu.g/ml.

14. The method of claim 6 wherein the erbB receptor activator is heregulin.

15. A method for isolating Schwann cells comprising:

(a) incubating nerve tissue containing the Schwann cells in serum-free culture medium which does not support the growth of fibroblasts, said incubation being for a period of time from about 1 day to about 5 days so that demyelination of the Schwann cells occurs, said culture medium comprising a nutrient solution for growing mammalian cells supplemented with a first mitogenic agent which is a Rse/Axl receptor activator and a second mitogenic agent; and

(b) culturing the demyelinated Schwann cells in the culture medium of (a).

16. The method of claim 15 wherein step (a) is preceded by a step wherein the nerve tissue is contacted with a protease for a period from about 10 minutes to about 100 minutes.

17. The method of claim 16 wherein the nerve tissue is contacted with collagenase and dispase prior to step (a).

18. The method of claim 15 wherein the culture medium additionally comprises heregulin, insulin and forskolin.

19. The method of claim 15 wherein step (b) comprises culturing the demyelinated Schwann cells in a laminin-coated culture plate.

20. A method for enhancing the survival or proliferation of Schwann cells in cell culture without supporting the growth of fibroblasts, said method comprising culturing the Schwann cells in serum free culture medium, wherein the culture medium comprises a nutrient solution for growing mammalian cells supplemented with an activator of the human Rse receptor, an erbB receptor activator and an agent which elevates cAMP levels, wherein the Rse receptor activator, the erbB receptor activator and the agent which elevates cAMP levels are each present in the culture medium in an amount effective to enhance survival or proliferation of the Schwann cells cultured therein.

21. The method of claim 20 wherein the Rse receptor activator is gas6.

22. The method of claim 21 wherein the concentration of gas6 in the culture medium is in the range from about 0.1 ng/ml to 100 ng/ml.

23. The method of claim 20 wherein the erbB receptor activator is heregulin.

24. The method of claim 23 wherein the heregulin is human heregulin-.beta.1.sub.177-244 fragment.

25. The method of claim 23 wherein the concentration of heregulin in the culture medium is in the range from about 0.1 nM to 50 nM.

26. The method of claim 20 wherein the agent which elevates cAMP levels is forskolin.

27. The method of claim 26 wherein the concentration of forskolin in the culture medium is in the range from 0.1 .mu.M to 50 .mu.M.

28. The method of claim 20 wherein said culture medium additionally comprises insulin or an insulin like growth factor, wherein the insulin or insulin like growth factor is present in the culture medium in an amount effective to enhance survival or proliferation of Schwann cells cultured therein.

29. The method of claim 20 wherein said culture medium additionally comprises insulin, wherein the concentration of insulin in the culture medium is in the range form 0.1 .mu.g/ml to 200 .mu.g/ml.

30. The method of claim 28 wherein said culture medium additionally comprises a molecule or composition which provides Fe ions to Schwann cells.

31. The method of claim 30 wherein the molecule or composition which provides Fe ions to the Schwann cells is transferrin.

32. The method of claim 30 wherein said culture medium additionally comprises progesterone, wherein the concentration of progesterone in the culture medium is in the range from 0.1 nM to 1000 nM.

33. The method of claim 32 wherein said culture medium additionally comprises Vitamin E, wherein the concentration of Vitamin E in the culture medium is in the range from 0.1 .mu.g/ml to 100 .mu.g/ml.

34. The method of claim 33 wherein said culture medium additionally comprises a protease inhibitor, wherein the concentration of protease inhibitor in the culture medium is in the range form 1 .mu.g/ml to 500 .mu.g/ml.

Details for Patent 5,721,139

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial Genentech, Inc. (South San Francisco, CA) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
McKinsey
McKesson
Baxter
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.